

Product Data Sheet

STING agonist-28

Cat. No.: HY-152961 CAS No.: 2868261-50-9

Molecular Formula: $C_{39}H_{46}N_{14}O_6$ Molecular Weight: 806.87

Target: STING

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN- β , IL-6, CXCL-10, TNF- α , ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1] .
In Vitro	STING agonist-28 (10 μ M; 3 h or 5 h) increases the level of phosphorylated STING, TBK1 and IRF3 following 3-h incubation, increases the level of IFN- β , IL- β , CXCL-10, TNF- α , ISG-15 following 5-h incubation, and CCL- β , in THP-1 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	STING agonist-28 adjuvant (20 μ g STING agonist-28 and 5 μ g RBD-Fc per mouse; im; 3 times at 14-day intervals) induces strong antibody immune response induced by the SARS-CoV-2 RBD-Fc protein in mice model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Liu Z, et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022 Mar;32(3):269-287.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA